Johnson & Johnson announced on Friday encouraging results from a Phase 2b study evaluating the efficacy and safety of the investigational monotherapy TAR-200 in patients with BCG-naive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for or refuse radical cystectomy.

' The high complete response rate and durability of responses observed in patients treated with TAR-200 underscore the potential of this therapeutic approach for HR-NMIBC patients not responding to BCG,' said Joseph Jacob, of Upstate Medical University's Department of Urology and author of the study.

''These results reinforce TAR-200's potential to transform the therapeutic landscape and our ongoing commitment to addressing the unmet needs of patients facing this challenging disease,'' added Christopher Cutie, vice president responsible for the bladder cancer disease area at Johnson & Johnson Innovative.

Copyright (c) 2024 CercleFinance.com. All rights reserved.